Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A comparative, double-blind, randomised, multicentre efficacy and safety study of ClairYg® versus Tégéline® in maintenance treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

    Summary
    EudraCT number
    2012-001996-34
    Trial protocol
    FR  
    Global end of trial date
    08 Jun 2015

    Results information
    Results version number
    v1(current)
    This version publication date
    13 Jul 2016
    First version publication date
    13 Jul 2016
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    IGNG-0904
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Other trial identifiers
    Short name: ECLIPSE
    Sponsors
    Sponsor organisation name
    LFB biotechnologies
    Sponsor organisation address
    3, avenue des tropiques - BP 40305, COURTABOEUF, France, 91958
    Public contact
    Global Clinical Development Leader, LFB BIOTECHNOLOGIES, 0033 169825656,
    Scientific contact
    Global Clinical Development Leader, LFB BIOTECHNOLOGIES, 0033 169825656,
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    15 Apr 2016
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    08 Jun 2015
    Global end of trial reached?
    Yes
    Global end of trial date
    08 Jun 2015
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    Primary objective: The primary objective is to assess the efficacy of ClairYg® in controlling the neurological status of patients with CIDP.
    Protection of trial subjects
    None
    Background therapy
    None
    Evidence for comparator
    Tegeline was the only intravenous immunoglobulin that had the indication "CIDP" when the study was started.
    Actual start date of recruitment
    23 Nov 2012
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    France: 40
    Worldwide total number of subjects
    40
    EEA total number of subjects
    40
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    24
    From 65 to 84 years
    16
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Recruited in France

    Pre-assignment
    Screening details
    -

    Pre-assignment period milestones
    Number of subjects started
    45 [1]
    Number of subjects completed
    40

    Pre-assignment subject non-completion reasons
    Reason: Number of subjects
    screening failure: 5
    Notes
    [1] - The number of subjects reported to have started the pre-assignment period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
    Justification: It was planned to screen 44 patients in order to have 40 randomised and assessable patients. It has been necessary to screen 45 patients in order to have 40 randomised patients.
    Period 1
    Period 1 title
    Before 1st administration of study drug
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator, Monitor, Data analyst, Carer, Assessor
    Blinding implementation details
    The hospital pharmacist was not blind and randomised the patient via an Interactive Voice Respose System (IVRS).

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Clairyg arm
    Arm description
    -
    Arm type
    Experimental

    Investigational medicinal product name
    Clairyg
    Investigational medicinal product code
    IGNG
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Patients were already under intravenous immunoglobulin when they were recruited. • The allowed range of doses per course was 0.4 to 2 g/kg • The allowed range of course frequency was every 2 to 9 weeks (during 6 months). During the study, the dose and course frequency was maintained at the same level as before the randomisation. The study drug was administered intravenously, with an infusion pump.

    Arm title
    Tégéline arm
    Arm description
    -
    Arm type
    Active comparator

    Investigational medicinal product name
    Tegeline
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Patients were already under intravenous immunoglobulin when they were recruited. • The allowed range of doses per course was 0.4 to 2 g/kg • The allowed range of course frequency was every 2 to 9 weeks (during 6 months). During the study, the dose and course frequency was maintained at the same level as before the randomisation. The study drug was administered intravenously, with an infusion pump.

    Number of subjects in period 1
    Clairyg arm Tégéline arm
    Started
    20
    20
    Completed
    20
    20
    Period 2
    Period 2 title
    Treatment period
    Is this the baseline period?
    No
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Investigator, Monitor, Data analyst, Carer, Assessor, Subject
    Blinding implementation details
    The hospital pharmacist was not blind and prepared the product to be administered in blind containers, ready for the administration to the patient.

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Clairyg arm
    Arm description
    -
    Arm type
    Experimental

    Investigational medicinal product name
    Clairyg
    Investigational medicinal product code
    IGNG
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Patients were already under intravenous immunoglobulin when they were recruited. • The allowed range of doses per course was 0.4 to 2 g/kg • The allowed range of course frequency was every 2 to 9 weeks (during 6 months). During the study, the dose and course frequency was maintained at the same level as before the randomisation. The study drug was administered intravenously, with an infusion pump.

    Arm title
    Tégéline arm
    Arm description
    -
    Arm type
    Active comparator

    Investigational medicinal product name
    Tegeline
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    Patients were already under intravenous immunoglobulin when they were recruited. • The allowed range of doses per course was 0.4 to 2 g/kg • The allowed range of course frequency was every 2 to 9 weeks (during 6 months). During the study, the dose and course frequency was maintained at the same level as before the randomisation. The study drug was administered intravenously, with an infusion pump.

    Number of subjects in period 2
    Clairyg arm Tégéline arm
    Started
    20
    20
    Completed
    18
    19
    Not completed
    2
    1
         Consent withdrawn by subject
    -
    1
         Exclusion criterion
    2
    -

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Before 1st administration of study drug
    Reporting group description
    -

    Reporting group values
    Before 1st administration of study drug Total
    Number of subjects
    40 40
    Age categorical
    Units: Subjects
        Adults (18-85 years)
    40 40
    Age continuous
    Units: years
        median (full range (min-max))
    63.5 (24 to 84) -
    Gender categorical
    Units: Subjects
        Male
    28 28
        Female
    12 12
    Subject analysis sets

    Subject analysis set title
    FAS Clairyg arm
    Subject analysis set type
    Full analysis
    Subject analysis set description
    All patients who received at least 1 administration of study drug and with at least one post baseline assessment of the primary efficacy endpoint

    Subject analysis set title
    FAS Tégéline arm
    Subject analysis set type
    Full analysis
    Subject analysis set description
    All patients who received at least one administration of study drug and with at least one post-baseline assessment of the primary efficacy endpoint

    Subject analysis set title
    PPS Clairyg arm
    Subject analysis set type
    Per protocol
    Subject analysis set description
    All patients in the FAS without any major protocol deviation

    Subject analysis set title
    PPS Tégéline arm
    Subject analysis set type
    Per protocol
    Subject analysis set description
    All patients in the FAS without any major protocol deviation

    Subject analysis set title
    Total treated set Clairyg arm
    Subject analysis set type
    Safety analysis
    Subject analysis set description
    All patients who received at least one administration of IMP

    Subject analysis set title
    Total treated set Tegeline arm
    Subject analysis set type
    Safety analysis
    Subject analysis set description
    All patients who received at least one administration of study drug

    Subject analysis sets values
    FAS Clairyg arm FAS Tégéline arm PPS Clairyg arm PPS Tégéline arm Total treated set Clairyg arm Total treated set Tegeline arm
    Number of subjects
    19
    20
    18
    19
    20
    20
    Age categorical
    Units: Subjects
        Adults (18-85 years)
    19
    20
    18
    19
    20
    20
    Age continuous
    Units: years
        median (full range (min-max))
    63.5 (24 to 74)
    63 (43 to 84)
    Gender categorical
    Units: Subjects
        Male
    13
    15
        Female
    7
    5

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Clairyg arm
    Reporting group description
    -

    Reporting group title
    Tégéline arm
    Reporting group description
    -
    Reporting group title
    Clairyg arm
    Reporting group description
    -

    Reporting group title
    Tégéline arm
    Reporting group description
    -

    Subject analysis set title
    FAS Clairyg arm
    Subject analysis set type
    Full analysis
    Subject analysis set description
    All patients who received at least 1 administration of study drug and with at least one post baseline assessment of the primary efficacy endpoint

    Subject analysis set title
    FAS Tégéline arm
    Subject analysis set type
    Full analysis
    Subject analysis set description
    All patients who received at least one administration of study drug and with at least one post-baseline assessment of the primary efficacy endpoint

    Subject analysis set title
    PPS Clairyg arm
    Subject analysis set type
    Per protocol
    Subject analysis set description
    All patients in the FAS without any major protocol deviation

    Subject analysis set title
    PPS Tégéline arm
    Subject analysis set type
    Per protocol
    Subject analysis set description
    All patients in the FAS without any major protocol deviation

    Subject analysis set title
    Total treated set Clairyg arm
    Subject analysis set type
    Safety analysis
    Subject analysis set description
    All patients who received at least one administration of IMP

    Subject analysis set title
    Total treated set Tegeline arm
    Subject analysis set type
    Safety analysis
    Subject analysis set description
    All patients who received at least one administration of study drug

    Primary: number of patients without relapse

    Close Top of page
    End point title
    number of patients without relapse [1]
    End point description
    End point type
    Primary
    End point timeframe
    number of patients without relapse in Clairyg arm and in Tégéline arm.
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: A purely descriptive comparison between Clairyg and Tegeline was choosen with a sample size of 40 evaluable patients choosen empirically. Tegeline and Clairyg primary efficacy endpoint was compared descriptively using an exact Fisher test with a two-sided 5% significance level.
    End point values
    FAS Clairyg arm FAS Tégéline arm PPS Clairyg arm PPS Tégéline arm
    Number of subjects analysed
    19
    20
    18
    19
    Units: number of no relapse
    18
    18
    17
    17
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    The investigators were instructed to record in the CRF all AEs that occurred after the patient signed the consent form. They reported a total of 162 treatment-emergent AEs that occurred in 26 patients (65%).
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    15.0
    Reporting groups
    Reporting group title
    Clairyg arm
    Reporting group description
    -

    Reporting group title
    Tégéline arm
    Reporting group description
    -

    Serious adverse events
    Clairyg arm Tégéline arm
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 20 (0.00%)
    2 / 20 (10.00%)
         number of deaths (all causes)
    0
    0
         number of deaths resulting from adverse events
    0
    0
    Cardiac disorders
    Hypertensive crisis
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences causally related to treatment / all
    0 / 0
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Superinfection
    Additional description: Superinfection of chronic obstructive pulmonary disease
         subjects affected / exposed
    0 / 20 (0.00%)
    1 / 20 (5.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 4%
    Non-serious adverse events
    Clairyg arm Tégéline arm
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    11 / 20 (55.00%)
    15 / 20 (75.00%)
    Nervous system disorders
    Headache
         subjects affected / exposed
    3 / 20 (15.00%)
    12 / 20 (60.00%)
         occurrences all number
    18
    46
    General disorders and administration site conditions
    Asthenia
         subjects affected / exposed
    1 / 20 (5.00%)
    2 / 20 (10.00%)
         occurrences all number
    3
    4
    Gastrointestinal disorders
    Nausea
         subjects affected / exposed
    0 / 20 (0.00%)
    4 / 20 (20.00%)
         occurrences all number
    0
    7

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    30 May 2013
    Amendement was issued with the main objective of reinforcing the safety monitoring of patients, following communications from health authorities related to thromboembolic events and haemolysis risks with IVIg infusions. Noteworthy, no individual case safety report with thromboembolic event or haemolysis was received by LFB Biotechnologies in any of the clinical trials conducted with ClairYg. The amendment added new exclusion criteria for patients at risk and new biological tests to more closely monitor these risks.
    24 Apr 2014
    The primary efficacy endpoint was modified because it was found to be not adapted to maintenance treatment with the minimal efficient dose. New primary efficacy endpoint: Proportion of patients with no relapse throughout the 6-month follow-up i.e. whose adjusted INCAT disability score: - remains at the same baseline level or improves or - increases by one point without reinforcement in CIDP treatment schedule

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 21:27:25 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA